Patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment now have a new oral treatment option, with the U.S. FDA’s approval of Novartis AG’s Rhapsido ...

Rhapsido is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved for chronic spontaneous urticaria (CSU).

The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic ...

The FDA approved remibrutinib, the first oral treatment for adults with persistent chronic spontaneous urticaria despite H1 ...

The Food and Drug Administration (FDA) has approved Rhapsido ® (remibrutinib) for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H 1 ...

The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients ...

Washington, DC, Oct. 01, 2025 (GLOBE NEWSWIRE) -- On this Urticaria Day (UDAY), the Asthma and Allergy Foundation of America (AAFA), We CU, and The Mast Cell Disease Society (TMS) aim to raise ...

Remibrutinib is the first Bruton tyrosine kinase inhibitor approved by the FDA for chronic spontaneous urticaria.

Novartis AG won US approval for a new treatment for a hives-like skin condition, bolstering the Swiss drugmaker’s push into ...

The twice-daily pill, Rhapsido, is approved for patients with symptoms of chronic spontaneous urticaria (CSU) despite ...

The FDA today approved remibrutinib (Rhapsido; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for the treatment of chronic spontaneous urticaria (CSU) in patients who remain ...

Novartis (NVS) announced that Rhapsido received U.S. FDA approval as an oral treatment for adult patients with chronic spontaneous urticaria who ...